Targinta is a preclinical stage oncology biotech company, developing first-in-class therapeutic antibodies and ADCs for treatment of aggressive cancers, such as glioblastoma and triple-negative breast cancer, based on a unique and patent-protected target. The pipeline includes TARG10, which is a function-blocking antibody in preclinical development targeting integrin α10. In addition, Targinta’s pipeline includes TARG9, an antibody-drug conjugate (ADC) targeting integrin α10. Targinta is a wholly owned subsidiary of Xintela AB (publ) and is headquartered in Lund, Sweden.
Company Details
- Employees
- 1
- Address
- Medicon Village, Lund,22381,sweden
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.targinta.se/
- Keywords
- Alligator Bioscience AB.
- HQ
- Lund
Targinta Ab Questions
Targinta Ab's website is https://www.targinta.se/
Targinta Ab's LinkedIn profile is https://se.linkedin.com/company/targinta-ab
Targinta Ab has
1 employees.
View email and phone details for 1
employees at Targinta Ab.
Targinta Ab's industry is
Biotechnology Research
Targinta Ab's top competitors are
Sinntaxis,
Alligator Bioscience Ab,
Saga Diagnostics,
Redoxis Ab,
Truly Labs,
Medicon Village,
Xintela Ab,
Biogaia Ab,
Rg Discovery,
Cantargia Ab.
Targinta Ab's categories are Biotechnology Research
